Sign In
Buy INCY
$119.80
-0.800 (-0.663%)
At Close: Aug 05, 2026
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders.
Incyte nears up to $2 billion deal for blood disorder biotech Star, FT reports
06:11am, Sunday, 07'th Jun 2026
US biotech Incyte Pharma is nearing a deal for up to $2 billion to buy blood disorder drug developer Star Therapeutics, the Financial Times reported on Sunday, citing people famil
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) today announced that pivotal Phase 2 results from the PROGRESS study evaluating zilurgiser
FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for ENDO 2026.
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (MonjuviÂ/Min
Incyte blood cancer drug combo reduces disease-progression risk but with high side-effect rate
08:02am, Saturday, 30'th May 2026
Incyte's Monjuvi as part of a multi-drug regimen that includes a chemotherapy standard of care for an aggressive form of non-Hodgkin lymphoma reduced the risk of disease progression, relapse or dea
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte's frontMIND trial found Tafasitamab (Monjuvi/Minjuvi) combo significantly prolongs progression-free survival in high-risk DLBCL patients.
Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report?
12:31pm, Thursday, 28'th May 2026
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Here's Why Incyte (INCY) is a Strong Momentum Stock
10:51am, Tuesday, 26'th May 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
09:00am, Tuesday, 26'th May 2026
Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026 at 8:40 a.m. E
Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out
12:02pm, Monday, 25'th May 2026
Incyte NASDAQ: INCY Chief Medical Officer Steven Stein outlined the company's development priorities across hematology, oncology and immunology, with a particular focus on its mutant CALR antibody 989
Here's Why Incyte (INCY) is a Strong Value Stock
10:41am, Friday, 22'nd May 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Incyte (INCY) is a Top Growth Stock for the Long-Term
10:46am, Thursday, 21'st May 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Inside Incyte's $120 Million AI For Drug Development Deal
12:10pm, Wednesday, 20'th May 2026
In this week's edition of InnovationRx, we look at a new AI drug development deal, a pill for sleep apnea, Commure's $7 billion valuation, and more. To get it in your inbox, subscribe here.
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
09:00am, Wednesday, 20'th May 2026
[url="]Incyte[/url] (Nasdaq:INCY) and [url="]Genesis Molecular AI[/url] today announced a significant expansion of their strategic collaboration building and d
